Updated Monday, 8/10 After an active July, the US IPO market is taking a breather. Three companies are scheduled to raise $2.5 billion in the week ahead, led by Chinese real estate giant KE Holdings (BEKE). KE Holdings...read more
ALX Oncology, a Phase 1 immuno-oncology biotech developing CD47 checkpoint inhibitors, raised $162 million by offering 8.5 million shares at $19, above the range of $15 to $17. The company offered 0.5 million more shares than anticipated. At pricing, the company...read more
ALX Oncology Holdings, a Phase 1 immuno-oncology biotech developing CD47 pathway-blocking therapies, announced terms for its IPO on Monday. The Burlingame, CA-based company plans to raise $128 million by offering 8 million shares at a price range of $15 to...read more
US IPO Week Ahead: The IPO market takes a breather in a 4 IPO week
Updated Monday, 8/10 After an active July, the US IPO market is taking a breather. Three companies are scheduled to raise $2.5 billion in the week ahead, led by Chinese real estate giant KE Holdings (BEKE). KE Holdings...read more
US IPO Weekly Recap: nCino pops 195% in 8 IPO week
Eight IPOs and six SPACs entered public markets this past week, led by nCino (NCNO), which ...read more
Immuno-oncology biotech ALX Oncology prices upsized IPO at $19, above the range
ALX Oncology, a Phase 1 immuno-oncology biotech developing CD47 checkpoint inhibitors, raised $162 million by offering 8.5 million shares at $19, above the range of $15 to $17. The company offered 0.5 million more shares than anticipated. At pricing, the company...read more
Immuno-oncology biotech ALX Oncology Holdings sets terms for $128 million IPO
ALX Oncology Holdings, a Phase 1 immuno-oncology biotech developing CD47 pathway-blocking therapies, announced terms for its IPO on Monday. The Burlingame, CA-based company plans to raise $128 million by offering 8 million shares at a price range of $15 to...read more